dotMD.com
✓ Translated by DotMD AI Clinical Council Source: CNS drugs • Phase III Randomized Trial
Verify Primary Source: NIH PubMed PMID #35380374
Plain-English Research Story • 8th-Grade Reading Level

Can This Approach Help? Inside the Latest Research on Effect of FT218, a Once-Nightly Sodium Oxybate Formulation, on Disrupted

The clinically beneficial, single nighttime dose of ON-SXB significantly improved disrupted nighttime sleep in patients with narcolepsy.

Original Paper Title: “Effect of FT218, a Once-Nightly Sodium Oxybate Formulation, on Disrupted Nighttime Sleep in Patients with Narcolepsy: Results from the Randomized Phase III REST-ON Trial” (CNS drugs, 2022-04-15)

Elena Rostova (AI Quant) Rigor Score
88 / 100
Sample Size (Participants)
N = 97
Evidence Classification
Phase III Randomized Trial
Sarah Jenkins, RN (AI Plain-English Editor) • Key Takeaways
  • The Bottom-Line Finding: The clinically beneficial, single nighttime dose of ON-SXB significantly improved disrupted nighttime sleep in patients with narcolepsy.
  • Who Was Studied: Phase III Randomized Trial published in CNS drugs following 97 real-world participants.
  • Strength of the Evidence: Earned a 88/100 Study Rigor Score based on trial design, sample size, and peer-reviewed controls.
  • Smart Next Step: Share this plain-English summary with your doctor or pharmacist before starting, stopping, or changing any treatment.
The Full Story in Plain English

What the Study Found (In Plain English)

Why This Matters to You

Sodium oxybate has been recognized as a gold standard for the treatment of disrupted nighttime sleep due to narcolepsy. When you or someone you love is weighing a treatment choice, dense medical journals can feel overwhelming. Yet the core question behind this research is one that everyday patients ask all the time: does this approach actually help you feel or function better—and is it safe?

How the Study Worked

To find out, researchers writing in CNS drugs conducted a phase iii randomized trial evaluating 97 real-world participants. Rather than relying on guesswork or anecdotal reports, the research team tracked measurable health outcomes and day-to-day side effects under controlled clinical conditions.

What the Study Found in Plain English

The clinically beneficial, single nighttime dose of ON-SXB significantly improved disrupted nighttime sleep in patients with narcolepsy. Instead of leaving patients in the dark, these results give you and your doctor concrete data you can weigh together.

The Catch: What to Keep in Mind

Even strong medical studies have limits. Every person's body handles medicines, supplements, and lifestyle changes differently depending on age, kidney and liver health, and other prescriptions in the medicine cabinet. What worked on average in a clinical study may still need a personalized dose or a different option for you.

Bottom Line: Your Next Step

Bring this summary to your next doctor or pharmacist visit. Ask: "Based on my health history and current medications, does this research apply to me?" You can also click the formal study link below to inspect the original peer-reviewed paper directly.

Dr. Lin (AI Evidence Lead): Statistical Endpoints & Numbers

Published in CNS drugs (2022-04-15) • Study Design: Phase III Randomized Trial • Participants: N = 97 • Biostatistical Rigor Score: 88/100. Primary Takeaway: The clinically beneficial, single nighttime dose of ON-SXB significantly improved disrupted nighttime sleep in patients with narcolepsy.

Study Limitations & Caveats Before You Act

While this phase iii randomized trial scored 88/100 for research quality, clinical trials follow strict rules that may not match every patient's daily life. Always check with your doctor or pharmacist for drug interactions and personal risk factors before acting on new research.

Formal Peer-Reviewed Study Reference
“Effect of FT218, a Once-Nightly Sodium Oxybate Formulation, on Disrupted Nighttime Sleep in Patients with Narcolepsy: Results from the Randomized Phase III REST-ON Trial”
Published in CNS drugs (2022-04-15) • PMID/ID: 35380374
Read Formal Study

Related DotMD Clinical Hubs & Price Ledgers

Transparent AI Research Council • Grounded on NIH / FDA / PubMed Data

Ask our AI Specialists anything about PMID 35380374: Can This Approach Help? Inside the Latest Research on Effect of FT218, a Once-Nightly Sodium Oxybate Formulation, on Disrupted

3 of 3 Free Questions Remaining